Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development

Expert Opin Investig Drugs. 2021 Feb;30(2):85-93. doi: 10.1080/13543784.2021.1865914. Epub 2020 Dec 28.

Authors

Ernest A Adeghate¹, Huba Kalász², Saeeda Al Jaberi¹, Jennifer Adeghate³, Kornelia Tekes⁴

Affiliations

¹ Department of Anatomy, College of Medicine & Health Sciences, United Arab Emirates University , Al Ain, United Arab Emirates.
² Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University , Budapest, Hungary.
³ Department of Ophthalmology, University of Pittsburgh School of Medicine , Pittsburgh, USA.
⁴ Department of Pharmacodynamics, Faculty of Pharmacy, Semmelweis University , Budapest, Hungary.

PMID: 33327794
DOI: 10.1080/13543784.2021.1865914

No abstract available

Keywords: T2DM comorbidities; Type 2 Diabetes mellitus; cardiovascular diseases; hypoglycemic agents; renal diseases, pharmacotherapy.

Publication types

Editorial

MeSH terms

Animals
Cardiovascular Diseases / prevention & control
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Nephropathies / prevention & control
Drug Development*
Humans
Hypoglycemic Agents / therapeutic use*

Substances

Hypoglycemic Agents